Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | ACE | P12821 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | AAK1 | Q2M2I8 | 4/20 | 0.34 |
| ▸ | SYK | P43405 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CA7 | P43166 | 1/20 | 0.33 |
| ▸ | APP | P05067 | 1/20 | 0.32 |
| ▸ | CTSS | P25774 | 1/20 | 0.32 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL406294 | 0.86 | ATM (0.35) | ATMACECYP3A4AAK1SYK | |
| SCHEMBL13811785 | 0.84 | ACE (0.36) | ATMACECYP3A4CA1CA2 | |
| SCHEMBL6957298 | 0.83 | ACE (0.50) | ACEMAPK1CTSS | |
| SCHEMBL22403247 | 0.83 | ACE (0.40) | ACECTSS | |
| SCHEMBL6950805 | 0.83 | ACE (0.50) | ACEMAPK1CTSS | |
| SCHEMBL8054432 | 0.79 | CTSS (0.40) | ACECTSS | |
| SCHEMBL4149607 | 0.78 | PIM1 (0.37) | — | |
| SCHEMBL8312657 | 0.75 | GPR119 (0.36) | — | |
| SCHEMBL16819882 | 0.75 | ACE (0.47) | ATMACECYP3A4MAPK1 | |
| SCHEMBL15426849 | 0.75 | ACE (0.47) | ATMACECYP3A4MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012035346-A1 | PRODRUGS OF GUANFACINE | SHIRE, LLC (US) | 2012-03-22 | — | — | WO | disclosed |
| US-20120065152-A1 | PRODRUGS OF GUANFACINE | SHIRE LLC (US) | 2012-03-15 | — | — | US | disclosed |
| US-20120065152-A1 | PRODRUGS OF GUANFACINE | SHIRE LLC (US) | 2012-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065152-A1 | PRODRUGS OF GUANFACINE | UGT1A6, GDA, UGT1A3 | ATM 3696/4885ACE 129/4885CYP3A4 203/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.